Pay in 4 interest-free payments of $7.50 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
PubMed Central PMCID: PMC4573555
is a potent and orally active protein kinase C inhibitor for the treatment of uveal melanoma
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
14 and 21 days) reduces radiation induced histological signs of pulmonary injury
Lenvatinib Mesylate - CAS# 857890-39-2 0077 PubMed Central PMCID: PMC4573555Lenvatinib Mesylate, CAS No. 857890 39 2, also known as E7080, is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR FLK 1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell
US$ 649.50
US$ 108.60